Review for 10.1186/s12876-017-0639-0 (2017)

Reviewer ’s report  
 
Title: Prokinetics for the Treatment of Functional Dyspepsia: Bayesian Network Meta -analysis  
 
Version: 0 Date: 26 Mar 2017  
 
Reviewer: Somchai leelakusolvong  
 
Reviewer's report:  
 
This is the first meta -analysis to demonstrate the comparative effectiveness of prokinetic in FD. 
In my view point, only some points to be considered including the discrimination of FD, the 
different per iod of time enrolled in this study (Rome I, II, and III) for FD which may influence 
the diagnosis of FD and treatment outcome.  Moreover, half of the studies enrolled in this study 
are from China (mainly itopride studies) which were not published in Englis h language might 
have some effects to the study in terms of understanding the study design, statistical and result. 
Finally, I accepted this manuscript without revision.  
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls ? 
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in  the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five year s received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in a ny way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding , or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you  can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
In this five years, I have received the honorarium or compensation from Abbott (Itopr ide), 
Janssen pharmaceutical company (Motilium, Domperidone) and Eisai pharmaceutical company 
(Mosapride) from the lecture and advisory board.  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, i f the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license  (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal